What Chemours (CC)'s PFAS Settlement Means For Shareholders

RBC downgraded Chemours to Sector Perform from Outperform, lowering its price target to $14 from $22. The firm cited weak titanium dioxide demand and challenges in the refrigerants business. Chemours is a chemical manufacturer.

Chemours Co (CC) shares dropped 2.5% premarket after RBC downgraded it to Sector Perform, citing weak TiO2 demand and reduced growth expectations. RBC cut its price target to $14 from $22 and lowered EBITDA estimates for Q3 and FY26-FY27, citing macro pressures and project delays. The analyst sees limited near-term upside and a fully valued stock at current levels.

Chemours, a chemical company, has been linked to PFAS contamination in the Cape Fear River, North Carolina, affecting drinking water and health. The state reached a $590M settlement with Chemours for damages. PFAS contamination has also been reported near Chemours' facilities worldwide, raising concerns about global environmental and health impacts. Chemours inherited cleanup liabilities from its former parent company, DuPont, after a 2015 spin-off.

Chemours allegedly violated a 2019 agreement by exceeding PFAS limits in North Carolina's Cape Fear River, according to environmental groups. Tests showed insufficient reductions in PFAS levels and GenX emissions. The groups demand state action, while Chemours denies violations. The company is also part of a $590M settlement for past pollution.

Cape Fear River Watch alleges Chemours has failed to meet pollution limits agreed upon in a 2019 consent order, claiming the company's groundwater and air emissions controls are inadequate. Chemours disputes these claims, stating it has spent $1.2 billion complying with the order. The environmental group filed a formal notice, citing high levels of PFAS in surface water and groundwater around the plant.

Chemours (CC) shares rose 3.10% after agreeing to a settlement with North Carolina and nearby communities over emissions. The stock is at $14.98, down 29.24% over 90 days. Analysts view it as undervalued at a fair value of $19.78, citing growth in advanced materials and cost optimization. However, PFAS liabilities and regulations pose risks.